NF2 and mesothelioma: To probe the efficacy of candidate compounds within the context of mesothelioma, evaluation was conducted in a preclinical model of PM driver mutations, with CRISPR/Cas9-mediated knockout (48) (KO) of tumour suppressor NF2 in non-malignant, MeT-5A mesothelial cells.